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Ovarian cancer
usefulness of abdominal 
symptoms in early diagnosis
In contrast to the predictable media coverage 
of Hamilton and colleagues’ claims about 
early detection of ovarian cancer,1 general 
practitioners are crying out for reliable 
information on the predictive value of symptoms 
to enable early diagnosis and select patients for 
further investigation.
One surprising omission from the study is 
a review of the community prevalence of the 
symptoms investigated. The prevalence of 
abdominal bloating in the control subjects 
was 2% (21 out of 1060 subjects). General 
practitioners active in clinical practice will 
find this surprisingly low, community surveys 
estimating it to be 16-30%.2 The positive 
predictive value for abdominal bloating that the 
authors calculate (0.3%) will be much lower if the 
prevalence of bloating is greater than the 2% in 
their controls.
They state: “Women with ovarian cancer 
usually have symptoms and report them 
to primary care, sometimes months before 
diagnosis.” But they found that women with 
ovarian cancer have the same variety of non-
specific symptoms that many women experience, 
that some of these symptoms (abdominal pain, 
distension, and loss of appetite) are substantially 
more common in the two or three months before 
diagnosis, and that one symptom (abdominal 
bloating) is more common for longer than this, 
but only compared with the surprisingly low 
prevalence in their controls. All of this makes 
their final rather emotive claim—“ovarian cancer 
is not silent, rather its sound is going unheard”—
and their comments to an unsceptical media 
rather surprising.
Graham Wheatley general practitioner, Munro Medical 
Centre, Spalding PE11 2BY gw1@mac.com
competing interests: None declared.
Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of 1 
ovarian cancer in women with symptoms in primary 
care: population based case-control study. BMJ 
2009;339:b2998. (25 August.)
Agrawal A, Whorwell PJ. Review article: abdominal 2 
bloating and distension in functional gastrointestinal 
disorders—epidemiology and exploration of possible 
mechanisms. Aliment Pharmacol Ther 2008;27:2-10.
Cite this as: BMJ 2009;339:b3954
Symptoms are not early signs 
of ovarian cancer
Hamilton and colleagues detected significant 
associations between bloating and increased 
abdominal distension and diagnosis of ovarian 
cancer,1 but these symptoms are not early 
signs of ovarian cancer but of advanced stage 
disease: an enlarged ovary, omental cake, or 
ascites. Visiting a doctor will result in diagnosis 
but not improved prognosis.
Bloating and abdominal distension are 
non-specific signs. Almost every woman has 
them in the second half of the menstrual cycle, 
and women with irritable bowel syndrome 
experience them frequently if not daily. As most 
women will not visit their general practitioners 
for these symptoms, this study cannot be 
regarded as population based.
Giving prominence to these non-specific 
signs and referring women to a gynaecologist for 
ultrasonography is not likely to be cost effective 
and will increase anxiety about cancer. On the 
basis of these results, abdominal distension 
and abdominal pain will yield, respectively, 
an additional 14 and 217 referrals yearly for 
each general practitioner. A prospective trial is 
needed to see whether such referrals result in 
earlier diagnosis of ovarian cancer.
We have more than 15 years’ experience 
in screening for ovarian cancer in a high risk 
population. Even with annual gynaecological 
screening and the possibility of visiting a doctor 
sooner if there are symptoms, we can only 
diagnose ovarian cancers at an advanced stage 
(IIIC).2 Therefore, instead of investing in late 
and non-specific signs and symptoms without 
proved efficacy in reducing mortality from 
ovarian cancer, we recommend investing in 
research on biomarkers to detect ovarian cancer 
at an early stage.
Marian J Mourits professor and gynaecological oncologist  
M.J.e.Mourits@og.umcg.nl 
Geertruida H de Bock associate professor and clinical 
epidemiologist, University Medical Centre Groningen, 
University of Groningen, Groningen, Netherlands
competing interests: None declared.
Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of 1 
ovarian cancer in women with symptoms in primary 
care: population based case-control study. BMJ 
2009;339:b2998. (25 August.)
Van der Velde NM, Mourits MJE, Arts HJG, De Vries J, 2 
Leegte LK, Dijkhuis G, et al. Time to stop ovarian cancer 
screening in BRCA1 and BRCA2 mutation carriers? Int J 
Cancer 2009;124:919-23.
Cite this as: BMJ 2009;339:b3955
Bran and irritaBle BOwels
Bran’s deleterious effects:  
much ado about nothing
Bijkerk and colleagues’ randomised 
controlled trial of soluble and insoluble fibre 
supplementation in irritable bowel syndrome 
is the first to be conducted entirely in primary 
care.1
In a systematic review and meta-analysis 
of trials in specialist settings, our group 
reported a beneficial effect of soluble 
fibre in the form of psyllium (or ispaghula 
husk) in irritable bowel syndrome with a 
number needed to treat (NNT) of 6 (95% 
confidence interval 3 to 50).2 Insoluble 
fibre in the form of bran was of no benefit, 
though we could not examine any potentially 
deleterious effect on symptoms suggested 
by some investigators3 because of the way 
in which data were reported. In Bijkerk and 
colleagues’ trial, the high dropout rates at 
12 weeks meant that the effects of ispaghula 
on abdominal pain or discomfort were 
only modest, but when these data were 
incorporated into our meta-analysis the NNT 
was similar (7 (4 to 25)).
Bijkerk and colleagues say that “bran 
showed no clinically relevant benefit, and 
many patients seemed not to tolerate bran.” 
However, the numerical difference was not 
significant. After 12 weeks, abdominal pain 
and discomfort were better with bran than 
either ispaghula or placebo in both the 
intention to treat and worst case analysis, and 
symptom severity scores for irritable bowel 
syndrome improved compared with placebo.
Some patients with irritable bowel 
syndrome in primary care thus seem to 
respond to insoluble fibre supplementation. 
Further study of its utility in a subgroup of 
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Alexander c Ford lecturer in medicine, Department of 
Academic Medicine, St James’s University hospital, leeds 
lS9 7tF 
Paul Moayyedi professor of gastroenterology, 
Gastroenterology Division, McMaster University, health 
Sciences Centre, hamilton, ON, Canada l8N 3Z5
competing interests: None declared.
Bijkerk CJ, de Wit NJ, Muris JWM, Whorwell PJ, Knotterus 1 
JA, Hoes AW. Soluble or insoluble fibre in irritable 
bowel syndrome in primary care? Randomised placebo 
controlled trial. BMJ 2009;339:b3154. (27 August.)
Ford AC, Talley NJ, Spiegel BMR, Foxx-Orenstein 2 
AE, Schiller L, Quigley EMM, et al. Effect of fibre, 
antispasmodics and peppermint oil in the treatment 
of irritable bowel syndrome: systematic review of the 
literature and meta-analysis. BMJ 2008;337:a2313.
Francis CY, Whorwell PJ. Bran and irritable bowel 3 
syndrome: time for reappraisal. Lancet 1994;344:39-40.
Cite this as: BMJ 2009;339:b3956
rOsiglitazOne and piOglitazOne
Beware fractures
Juurlink and colleagues show that pioglitazone 
has fewer adverse cardiovascular outcomes 
than rosiglitazone, which may be a class 
effect.1 However, recent reports show that 
thiazolidinediones are associated with increased 
incidence of fractures.
By 2007 the manufacturers of pioglitazone 
had advised health professionals about the risk 
of fractures in women on the basis of clinical trial 
data outcomes.2 Recent reports show that both 
men and women who take thiazolidinediones 
for diabetes could be at increased risk of distal 
fractures of upper and lower limbs,3-5 the risk 
increasing with age.
The black box warning from the US Food 
and Drug Administration a few years after 
the introduction of thiazolidinediones, the 
withdrawal of troglitazone because of rare cases 
of severe hepatotoxicity, and the increased 
risk of fractures have raised concerns. Do the 
benefits of treatment outweigh the risks? Are 
thiazolidinediones the treatment of choice for 
type 2 diabetes?
Alok Dixit assistant professor  
Pinki Pandey assistant professor, M M institute of Medical 
Science and research, Mullana, Ambala, india 133203
competing interests: None declared.
Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, 1 
Mamdani MM. Adverse cardiovascular events during 
treatment with pioglitazone and rosiglitazone: population 
based cohort study. BMJ 2009;339:b2942. (18 August.)
Pioglitazone. 2 WHO Pharmaceuticals Newsletter 2007;3:5.
Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. 3 
Thiazolidinediones and fractures in men and women. Arch 
Intern Med 2009;169:1395-402.
Jones SG, Momin SR, Good MW, Shea TK, Patric K. 4 
Distal upper and lower limb fractures associated with 
thiazolidinedione use. Am J Manag Care 2009;15:491-6.
Loke YK, Sinkh S, Furberg CD. Long term use of 5 
thiazolidinediones and fractures in type 2 diabetes: a 
meta-analysis. CMAJ 2009;180:32-9.
Cite this as: BMJ 2009;339:b3957
interventiOns and knee pain
When knee pain is not 
osteoarthritis
Jenkinson and colleagues show that a 
simple dietary and exercise intervention has 
positive effects on knee pain.1 Over half of 
their unselected group, however, did not 
have radiological evidence of osteoarthritis. 
This shows that practitioners should always 
consider intra-articular and periarticular soft 
tissue problems and referred pain from other 
musculoskeletal regions. This large group 
might have a range of potentially self limiting 
soft tissue disorders skewing the observed 
improvements. This could be determined by 
interim analysis of WOMAC pain scores and 
functioning in those with low Kellgren-Lawrence 
scores at six or 12 months, thus identifying the 
characteristics of a better prognostic group.
In such a varied group, how is a poorer 
prognostic group defined? The authors have 
previously examined the role of muscle 
power and knee pain,2 muscle strength being 
significantly higher in the exercise group, 
although baseline values were not presented.3 
Higher WOMAC pain scores and lower muscle 
strength might be expected in the group with 
higher radiographic scores, but this caveat 
may not necessarily hold true. Furthermore, 
muscle weakness may initiate and perpetuate 
the progression of osteoarthritis,4 so to target 
muscle strength5 and weight loss in the group 
with low pain scores and evident radiographic 
change may be a worthwhile preventive 
strategy.
This brief intervention strategy would be 
implemented in primary care or outpatient 
clinics. In a fashion akin to salivary thiocyanate 
assays in smokers, could a quick bedside 
measure of extensor strength be a modifiable 
and predictive surrogate for compliance with 
an exercise programme alongside traditional 
measures such as weight and blood pressure?
Derek Baxter clinical research fellow, Centre for rheumatic 
Diseases, Glasgow royal infirmary, Glasgow G4 0SF 
desmondo90@hotmail.com
competing interests: None declared.
Jenkinson CM, Doherty M, Avery AJ, Read A, Taylor 1 
MA, Sach TH, et al. Effects of dietary intervention and 
quadriceps strengthening exercises on pain and function 
in overweight people with knee pain: randomised 
controlled trial. BMJ 2009;339:b3170. (18 August.)
O’Reilly SC, Jones A, Muir KR, Doherty M. Quadriceps 2 
weakness in knee osteoarthritis: the effect on pain and 
disability. Ann Rheum Dis 1998;57:588-94.
Thomas KS, Muir KR, Doherty M, Jones AC, O’Reilly SC, 3 
Bassey EJ. Home based exercise programme for knee 
pain and knee osteoarthritis: randomised controlled 
trial. BMJ 2002;325:752.
Slemenda C, Brandt KD, Heilman DK, Mazzuca S, 4 
Braunstein EM, Katz BP, et al. Quadriceps weakness 
and osteoarthritis of the knee. Ann Intern Med 
1997;127:97-104.
Mikesky AE, Mazzuca SA, Brandt KD, Perkins SM, 5 
Damush T, Lane KA. Effects of strength training on 
the incidence and progression of knee osteoarthritis. 
Arthritis Rheum 2006;55:690-9.
Cite this as: BMJ 2009;339:b3978
sarcOidOsis
technique to enable diagnosis
Conventional flexible bronchoscopy is of 
limited yield in diagnosing sarcoidosis when 
central or peripheral airways are not affected.1 
However, endobronchial ultrasound guided 
transbronchial needle aspiration may be 
helpful in patients with clinical sarcoidosis and 
computed tomographic evidence of accessible 
mediastinal nodes. We have confirmed the 
diagnosis of sarcoidosis using this technique, 
obviating the need for mediastinoscopy in 
seven out of nine such cases (table).
Positive histology was regarded as the 
presence of non-caseating granulomas with 
negative results in fungal and mycobacterial 
stains and cultures, and supportive clinical 
findings with no other clinical explanation for 
the granulomas. Chest computed tomograms 
in all cases showed mediastinal nodes with 
sarcoid-like changes without accessible 
parenchymal infiltrates or evidence of 
endobronchial involvement.
Details of nine cases of suspected sarcoidosis with 






1 7 2 Non-caseating 
granulomas
2 7 2 Non-caseating 
granulomas
3 4R, 7 2.5 Non-caseating 
granulomas 
4 3, 7, 10R 2 Non-caseating 
granulomas
5 7, 10R, 10L 3 Non-caseating 
granulomas
6 7, 10R 4 Non-caseating 
granulomas
7 7, 10R 3 Non-caseating 
granulomas
8 4L 2 Lymphocytes
9 4R 3 Lymphocytes
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Our findings are supported by several 
studies showing sensitivities of between 
83% and 93% for endobronchial ultrasound 
guided transbronchial needle aspiration, as 
well as its superiority over other techniques 
for stage 1 sarcoid, particularly conventional 
transbronchial needle aspiration.2-5 It may be 
a reasonable and cost effective treatment of 
choice  for patients with suspected sarcoidosis 
with mediastinal lymphadenopathy in whom 
transbronchial biopsy or endobronchial biopsy 
are unlikely to be fruitful.
Andrew r l Medford locum consultant chest physician, 
Department of respiratory Medicine, Glenfield hospital, 
leicester lE3 9QP andrewmedford@hotmail.com 
Sanjay Agrawal consultant respiratory intensivist, 
Jonathan A Bennett consultant respiratory physician, North 
Bristol lung Centre, Southmead hospital, Bristol BS10 5NB
competing interests: None declared.
Dempsey OJ, Paterson EW, Kerr KM, Denison AR. 1 
Sarcoidosis. BMJ 2009;339:b3206. (28 August.)
Nakajima T, Yasufuku K, Kurosu K, Takiguchi Y, Fujiwara 2 
T, Chiyo M, et al. The role of EBUS-TBNA for the diagnosis 
of sarcoidosis—comparisons with other bronchoscopic 
diagnostic modalities. Respir Med (in press).
Tremblay A, Stather DR, Maceachern P, Khalil M, 3 
Field SK. A randomized controlled trial of standard vs 
endobronchial ultrasonography-guided transbronchial 
needle aspiration in patients with suspected 
sarcoidosis. Chest 2009;136:327-8.
Oki M, Saka H, Kitagawa C, Tanaka S, Shimokata T, 4 
Kawata Y, et al. Real-time endobronchial ultrasound-
guided transbronchial needle aspiration is useful for 
diagnosing sarcoidosis. Respirology 2007;12:863-8.
Garwood S, Judson MA, Silvestri G, Hoda R, Fraig M, 5 
Doelken P. Endobronchial ultrasound for the diagnosis 
of pulmonary sarcoidosis. Chest 2007;132:1298-304.
Cite this as: BMJ 2009;339:b3962
FrOm sick nOtes tO Fit nOtes
Bridging the chasm
As a former manager in a multinational 
manufacturing company, I find the concept of a 
fit note laudable.1 As a medical student currently 
on elective in occupational health, I can see the 
resources and knowledge required to make it 
work is more like bridging a chasm than a gap.
Most of the employers I have spoken to are 
frustrated with the current sick note system and 
general practitioners’ readiness to sign people 
off. Most of the general practitioners I have 
spoken to are frustrated that they don’t know 
enough about a patient’s work content or work 
environment to do otherwise. This knowledge 
gap is not surprising—most medical students 
do not study occupational health—but it should 
be rectified. Some excellent postgraduate 
courses are available, but only one (at 
Manchester) allows distance learning. Perhaps 
the government should encourage general 
practitioners to complete courses and enter 
into appropriate dialogue with their patients’ 
employers.
A new referral system to an occupational 
health service is indeed useful.1 Most larger 
employers already buy in these services, and 
general practitioners may not be aware that they 
could refer their patients (with consent) should 
they have any doubts about the patient’s 
capabilities.
The combined resources of NHS and 
private occupational health services 
would not meet the demand generated by 
introducing fit notes. Challenges include 
promoting the specialty; providing adequate 
training places, almost certainly with 
the help of the private sector; ensuring 
availability of postgraduate courses; and 
providing help for small businesses to 
appreciate the benefits.
Ian Buchanan fifth year medical student, Peninsula 
Medical School, Plymouth Pl6 8BU  
ian.buchanan@students.pms.ac.uk
competing interests: None declared.
Verbeek J, Madan I. From sick notes to fit notes. 1 BMJ 
2009;339:b3114. (10 August.)
Cite this as: BMJ 2009;339:b3971
Not a simple answer
Fit notes look simple but are likely to be 
problematic for employers, employees, and 
general practitioners.1
I have been a general practitioner since 
1974 and a part-time factory medical officer 
for the main local employer for over 20 years. 
Knowing the nature of my patients’ tasks at 
work makes advising on returning to work 
after sick leave much easier and more useful. 
In the occupational health department I 
can advise on graded work to enable return 
to full function in the shortest time—to 
the benefit of employees and employer. 
Knowing all the local general practitioners, 
I can advise them, subject to consent, how 
to help their patients to return to work as 
early as possible. Departmental managers 
usually accommodate any initial restrictions 
or arrange alternative work if available, and 
occupational health nurses are invaluably 
supportive.
This set-up is not widely available. For 
general practitioners to issue fit notes seems 
simplistic if they do not have training in 
occupational health and do not know what 
their patients’ work entails. Employers and 
general practitioners will easily become 
frustrated without advice from occupational 
health. Fit notes might be better issued 
by occupational physicians, perhaps with 
referral from general practitioners. But 
are there enough professionals trained in 
occupational health?
John Merrick locum general practitioner, Somerset 
john@68leigh.freeserve.co.uk
competing interests: None declared.
Verbeek J, Madan I. From sick notes to fit notes. 1 BMJ 
2009;339:b3114. (10 August.)
Cite this as: BMJ 2009;339:b3972
asBestOs and the lung
Diffuse pleural thickening has 
new definition for claims
Currie and colleagues define diffuse pleural 
thickening in a chest radiograph as “a smooth 
continuous pleural density affecting 25% of 
the lateral chest wall, with or without blunting 
of the costophrenic angle.”1
The definition was changed by the 
Department for Work and Pensions for the 
purposes of  industrial injuries disability benefit 
for prescribed disease D9 in July 2005, and 
was passed by parliament in April 2006. It is 
currently “unilateral or bilateral diffuse pleural 
thickening with obliteration of the costophrenic 
angle.”2 Previously it was pleural thickening (of 
5 mm or more in a standard chest radiograph) 
covering 25% or more of the combined area of 
the chest wall of both lungs if bilateral, or 50% 
or more if unilateral.2
Although computed tomography may 
be used to further substantiate a claim, 
compensation is usually awarded on the 
basis of standard chest radiography alone 
and the extent of respiratory disability. The 
rules for disability claims for asbestos related 
lung cancer also changed in April 2006.3
Jennifer l Hoyle consultant physician  
jennifer.hoyle@pat.nhs.uk 
Jonathan K r Walker respiratory registrar, North 
Manchester General hospital, Manchester M8 5rB
competing interests: None declared.
Currie GP, Watt SJ, Maskell NA. An overview of 1 
how asbestos exposure affects the lung. BMJ 
2009;339:b3209. (24 August.)
Newman Taylor AJ, chairman. Department for Work 2 
and Pensions Social Security Administration Act 1992. 
Completion of the review of the scheduled list of 
prescribed diseases. Report by the Industrial Injuries 
Advisory Council in accordance with Section 171 of 
the Social Security Administration Act 1992 marking 
the completion of the review of the scheduled list of 
prescribed diseases. www.official-documents.gov.uk/
document/cm70/7003/7003.pdf
Industrial Injuries Advisory Council. Reports. www.iiac.org.3 
uk/reports/index.asp
Cite this as: BMJ 2009;339:b3953
unilateral obliteration of right hemi-diaphragm with 
diaphragmatic calcification on the right and pleural 
plaques (large one on the left)




The fever of flu may mimic neutropenic fever. 
Therefore a policy for managing fever during the 
A/H1N1 flu pandemic in patients with cancer who 
are receiving chemotherapy has been developed 
with detailed advice from Professor Nick Phin and 
Dr Hongxin Zhao of the Health Protection Agency.
Patients receiving chemotherapy who develop 
a fever should telephone the emergency number 
of their haematology or oncology unit for advice, 
not the National Pandemic Flu Service.1
If assessed in hospital, patients should wear 
a surgical mask and be seen in a single room 
by healthcare professionals using personal 
protective equipment. A virological swab should 
be taken and biochemical tests ordered in 
addition to the usual tests. Other identified 
causes of fever with a normal or raised neutrophil 
count should be treated as appropriate.
Patients who are not neutropenic and may 
have flu should be sent home with a course of 
oseltamivir, given at the point of contact with 
the hospital and with advice to self isolate and 
to take general respiratory and personal hygiene 
measures.
Patients with neutropenia should be admitted 
with institution of infection control measures. 
The microbiologist should be informed, and 
the neutropenia treated according to the usual 
protocol with the addition of oseltamivir.
Patients with laboratory confirmed A/H1N1 
pandemic flu whose condition does not improve 
or deteriorates with antiviral treatment should 
telephone their unit’s emergency telephone 
number. They should attend for reassessment, 
including a repeat blood count, cultures, and a 
viral swab. Some of the material should be sent to 
a laboratory that can detect antiviral resistance. 
Zanamivir by inhalation should be considered 
after consultation with a microbiologist 
or virologist, whether or not the patient is 
neutropenic.
S Michael crawford consultant medical oncologist, Airedale 
General hospital, Keighley, West Yorkshire BD20 6tD 
michael.crawford@anhst.nhs.uk
competing interests: None declared.
Elliot AJ, Powers C, Thornton A, Obi C, Hill C, Simms 1 
I, et al. Monitoring the emergence of community 
transmission of influenza A/H1N1 2009 in England: a 
cross sectional opportunistic survey of self sampled 
telephone callers to NHS Direct. BMJ 2009;339:b3403. 
(27 August.)
Cite this as: BMJ 2009;339:b3960
A/H1N1 and other viruses 
affecting cystic fibrosis
For over 12 months all patients attending our 
regional cystic fibrosis unit have had throat 
swabs analysed routinely for viruses with the 
polymerase chain reaction before 
starting intravenous antibiotics. 
We assessed the prevalence 
of A/H1N1 flu virus1 in acute 
severe exacerbations of cystic 
fibrosis.
The first case of A/H1N1 flu 
in Leeds was confirmed on the 7 
June 2009. Since then, 187 adult 
patients have had pulmonary 
exacerbations requiring intravenous 
antibiotics. Fifteen had positive viral 
swabs. Four of them tested positive for A/H1N1 
flu virus, one of whom was immunosuppressed 
after lung transplantation and presented with 
fever, breathlessness, vomiting, and headache. 
Eight patients were positive for rhinovirus, two 
for adenovirus, and one for parainfluenza virus. 
Repeat swabs remained positive in two patients 
with A/H1N1 flu virus four and six weeks later.
A/H1N1 flu virus has caused only a few acute 
pulmonary exacerbations of cystic fibrosis. If 
the prevalence of viral infections was similar in 
the community, antiviral drugs are likely to have 
been overprescribed and people might decline 
vaccination because they believe that they have 
already had the infection. Prolonged infection 
in at risk patients needs further investigation2 
but shows the importance of vaccination in 
vulnerable groups.
Paul Whitaker Spr in respiratory medicine 
drpaulwhitaker@hotmail.com 
christine etherington associate specialist, regional Adult 
Cystic Fibrosis Unit, St James’s hospital, leeds lS9 7tF 
Miles Denton consultant microbiologist, Department of 
Microbiology, leeds General infirmary, leeds lS1 3EX 
Steven conway consultant physician 
Daniel Peckham consultant physician, regional Adult 
Cystic Fibrosis Unit, St James’s hospital, leeds lS9 7tF
competing interests: None declared.
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E, Latiff K, et al. Persistence of rhinovirus RNA after 
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By any maths would  
be as weak
Information from New Zealand and New York City 
seems to show that 20 000-30 000 people are 
infected with this pandemic construct for each 
death.1-3
Approximately 3000 deaths have been 
confirmed,4 suggesting that between 60 
million and 90 million people have already 
been infected by the 2009 H1N1 pandemic flu 
virus.
The 595 deaths5 in the United 
States equates to 12 million to 18 
million infections in the US alone.
By any measure A/H1N1 is 
a benign flu virus. According 
to official statements, New 
Zealand, for example, usually 
has 400 deaths from flu each 
year. This year there were 17,2 
so it could be argued that the 
pandemic has resulted in 383 lives 
being saved, which makes it more effective 
than any flu vaccine.
ron law risk and policy consultant, Auckland, New Zealand 
juderon@gmail.com
competing interests: None declared.
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drug preventiOn OF hypertensiOn
contradicting cochrane
Law and colleagues’ conclusion that “drugs 
are offered to people of all levels of blood 
pressure” seems to contradict that of a more 
recent Cochrane review on blood pressure 
targets for the treatment of hypertension.1 
This systematic review, which seems 
to consider the same data as Law and 
colleagues, concludes: “Treating patients to 
lower than standard blood pressure targets, 
≤140-160/90-100 mm Hg, does not reduce 
mortality or morbidity. Because guidelines are 
recommending even lower targets for diabetes 
mellitus and chronic renal disease, we are 
currently conducting systematic reviews in 
those groups of patients.”2
As generalists, we find these conflicting 
conclusions disturbing. Who is right?
ray F o’connor general practitioner 
rocthedoc@eircom.net 
ruth Moloney trainee general practitioner, Mid-West 
Specialist training Programme in General Practice, University 
of limerick, limerick, republic of ireland
competing interests: None declared.
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